170 related articles for article (PubMed ID: 37171617)
61. Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells.
Shannon S; Vaca C; Jia D; Entersz I; Schaer A; Carcione J; Weaver M; Avidar Y; Pettit R; Nair M; Khan A; Foty RA
PLoS One; 2015; 10(8):e0135951. PubMed ID: 26284619
[TBL] [Abstract][Full Text] [Related]
62. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
63. The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion.
Jermakowicz AM; Rybin MJ; Suter RK; Sarkaria JN; Zeier Z; Feng Y; Ayad NG
Sci Rep; 2021 Dec; 11(1):23370. PubMed ID: 34862404
[TBL] [Abstract][Full Text] [Related]
64. Korean Red ginseng extract inhibits glioblastoma propagation by blocking the Wnt signaling pathway.
Ham SW; Kim JK; Jeon HY; Kim EJ; Jin X; Eun K; Park CG; Lee SY; Seo S; Kim JY; Choi SH; Hong N; Lee YY; Kim H
J Ethnopharmacol; 2019 May; 236():393-400. PubMed ID: 30878548
[TBL] [Abstract][Full Text] [Related]
65. Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.
Bagó JR; Pegna GJ; Okolie O; Mohiti-Asli M; Loboa EG; Hingtgen SD
Biomaterials; 2016 Jun; 90():116-25. PubMed ID: 27016620
[TBL] [Abstract][Full Text] [Related]
66. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
67. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
68. Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.
Lim YC; Ensbey KS; Offenhäuser C; D'souza RCJ; Cullen JK; Stringer BW; Quek H; Bruce ZC; Kijas A; Cianfanelli V; Mahboubi B; Smith F; Jeffree RL; Wiesmüeller L; Wiegmans AP; Bain A; Lombard FJ; Roberts TL; Khanna KK; Lavin MF; Kim B; Hamerlik P; Johns TG; Coster MJ; Boyd AW; Day BW
Neuro Oncol; 2020 Feb; 22(2):216-228. PubMed ID: 31504812
[TBL] [Abstract][Full Text] [Related]
69. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL
Sci Rep; 2019 Feb; 9(1):2905. PubMed ID: 30814573
[TBL] [Abstract][Full Text] [Related]
70. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S
Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675
[TBL] [Abstract][Full Text] [Related]
71. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Lescarbeau RS; Lei L; Bakken KK; Sims PA; Sarkaria JN; Canoll P; White FM
Mol Cancer Ther; 2016 Jun; 15(6):1332-43. PubMed ID: 27196784
[TBL] [Abstract][Full Text] [Related]
72. Biobanking: An Important Resource for Precision Medicine in Glioblastoma.
Tan SY; Sandanaraj E; Tang C; Ang BT
Adv Exp Med Biol; 2016; 951():47-56. PubMed ID: 27837553
[TBL] [Abstract][Full Text] [Related]
73. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
74. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo.
Denicolaï E; Baeza-Kallee N; Tchoghandjian A; Carré M; Colin C; Jiglaire CJ; Mercurio S; Beclin C; Figarella-Branger D
Oncotarget; 2014 Nov; 5(21):10934-48. PubMed ID: 25400117
[TBL] [Abstract][Full Text] [Related]
75. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
[TBL] [Abstract][Full Text] [Related]
76. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
77. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma.
Li Z; Mbah NE; Overmeyer JH; Sarver JG; George S; Trabbic CJ; Erhardt PW; Maltese WA
BMC Cancer; 2019 Jan; 19(1):77. PubMed ID: 30651087
[TBL] [Abstract][Full Text] [Related]
78. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
[TBL] [Abstract][Full Text] [Related]
79. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Sabelström H; Quigley DA; Fenster T; Foster DJ; Fuchshuber CAM; Saxena S; Yuan E; Li N; Paterno F; Phillips JJ; James CD; Norling B; Berger MS; Persson AI
Exp Cell Res; 2019 May; 378(1):76-86. PubMed ID: 30844389
[TBL] [Abstract][Full Text] [Related]
80. Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Zhao SG; Yu M; Spratt DE; Chang SL; Feng FY; Kim MM; Speers CW; Carlson BL; Mladek AC; Lawrence TS; Sarkaria JN; Wahl DR
Neuro Oncol; 2019 Sep; 21(9):1141-1149. PubMed ID: 31121035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
